Director, Health Economics and Outcomes Research
Alkermes
Waltham, Massachusetts
Michael Doane, Ph.D, is an Associate Director of Health Economics and Outcomes Research (HEOR) at Alkermes, Inc. He conducts HEOR-related activities supporting ALKS 3831, which is an investigational, novel oral atypical antipsychotic drug candidate for the treatment of schizophrenia. His expertise is in the use and analysis of patient-reported outcome measures to quantify disease burden and identify unmet patient needs.
He was previously a Manager of Health Outcomes Research at Kantar Health with experience evaluating the humanistic and economic impact of medical conditions and their treatments. In his client-facing role, he collaborated with pharmaceutical and biotechnology companies to develop research strategies that support pharmaceutical products across their lifecycles. He gained experience generating real-world evidence through rigorous quantitative methods across various therapeutic areas (e.g., oncology, psychiatry/psychology, cardiovascular diseases, rare diseases, and diabetes). Projects included: custom observational studies among patients, caregivers, and physicians, patient preference studies, physician chart reviews, and analyses of medical claims.
Tuesday, May 2, 2023
2:15 PM – 3:15 PM
.png)
